SurvivorNet on MSN
‘An opportunity to stay one step ahead’: FDA approves camizestrant at first sign of treatment resistance for many with advanced breast cancer
The FDA granted accelerated approval to camizestrant (Etcamah) for certain breast cancer patients who develop an ESR1 ...
Dr. Angelo de Claro of the FDA's Oncology Center of Excellence, in a news release, said, "This marks the first FDA approval ...
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...
The FDA has granted accelerated approval to Etcamah for certain patients with ESR1-mutated, HR-positive, HER2-negative advanced breast cancer.
Hot on the heels of the approval for AstraZeneca’s breast cancer drug Etcamah, Guardant Health has been given the green light ...
The U.S. Food and Drug Administration has expanded treatment options for adult patients with advanced breast cancer, ...
MedPage Today on MSN
Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors
Oral SERD camizestrant lands indication for use in novel first-line treatment strategy ...
AstraZeneca’s Etcamah in combination with a CDK4/6 inhibitor receives US FDA approves for 1st-line advanced HR-positive breast cancer: Cambridge, UK Monday, September 7, 2026, 1 ...
Drugmaker AstraZeneca said on Monday that its breast cancer drug Etcamah (camizestrant), used alongside a CDK4/6 inhibitor, ...
GlobalData on MSN
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The approval is based on findings from the SERENA-6 Phase III trial.
The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked ...
AstraZeneca said late Friday that the United States has approved its Etcamah (camizestrant), in combination with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results